Jia Ren-Bing, Fan Xian-Qun, Wang Xiao-Li, Zhang Xing-Qian, Zhang Ping, Lu Jian
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200011, China.
Zhonghua Yan Ke Za Zhi. 2007 Jun;43(6):493-8.
To explore the inhibition effect of small hairpin RNA (shRNA) expression plasmid targeting vascular endothelial growth factor (VEGF) on VEGF expression in cultured retinoblastoma (RB) cells.
VEGF shRNA plasmid p4.1CMV-VEGF was constructed and transfected into retinoblastoma cell lines SO-RB50 and HXO-RB44. Using neomycin G418 in conjunction with gradient dilution, p4.1CMV-VEGF shRNA positive single clone of RB cells was selected and subsequently enriched. Real-time polymerase chain reaction (PCR) was applied to detect VEGF mRNA levels of RB cells. VEGF protein concentration in culture supernatants of RB cells were determined by enzyme-linked immunosorbent assay (ELISA). Plasmid p4.1CMV-Neg shRNA, which expressed shRNA lacking significant sequence identity to human and mouse genome databases, was transfected into RB cells as negative control. Cells without any treatment were used as blank controls.
p4.1CMV-VEGF shRNA was constructed successfully and VEGF shRNA construct positive clone of RB cells was developed. VEGF mRNA level of SO-RB50 (HXO-RB44) cells in negative control and blank control was 5.02 (5.70) folds and 6.32 (4.86) folds greater than that in p4.1CMV-VEGF shRNA treated SO-RB50 (HXO-RB44) cells. VEGF protein concentration in culture supernatants of p4.1CMV-VEGF shRNA treated SO-RB50 cells (187.69 +/- 83.89) microg/L was significantly lower than that of negative control (822.98 +/- 187.98) microg/L and blank control (865.76 +/- 170.33) microg/L (P < 0.01). There was also significant difference of VEGF protein concentration between p4.1CMV-VEGF shRNA treated HXO-RB44 cells (162.20 +/- 66.33) microg/L and controls (764.33 +/- 164.79) microg/L in negative control and (828.22 +/- 145.94) microg/L in blank control (P < 0.01).
Stable transfection of VEGF shRNA expression plasmid can potently suppress VEGF expression in RB cells. RNA interference (RNAi) targeting VEGF promises to be a substantial tool for the study of the treatment of RB.
探讨靶向血管内皮生长因子(VEGF)的小发夹RNA(shRNA)表达质粒对培养的视网膜母细胞瘤(RB)细胞中VEGF表达的抑制作用。
构建VEGF shRNA质粒p4.1CMV-VEGF,并将其转染至视网膜母细胞瘤细胞系SO-RB50和HXO-RB44。联合使用新霉素G418及梯度稀释法,筛选并富集RB细胞的p4.1CMV-VEGF shRNA阳性单克隆。应用实时聚合酶链反应(PCR)检测RB细胞的VEGF mRNA水平。采用酶联免疫吸附测定(ELISA)法测定RB细胞培养上清液中的VEGF蛋白浓度。将表达与人和小鼠基因组数据库无明显序列同源性的shRNA的质粒p4.1CMV-Neg shRNA转染至RB细胞作为阴性对照。未作任何处理的细胞作为空白对照。
成功构建p4.1CMV-VEGF shRNA,并获得RB细胞的VEGF shRNA构建体阳性克隆。阴性对照和空白对照中SO-RB50(HXO-RB44)细胞的VEGF mRNA水平分别比p4.1CMV-VEGF shRNA处理的SO-RB50(HXO-RB44)细胞高5.02(5.70)倍和6.32(4.86)倍。p4.1CMV-VEGF shRNA处理的SO-RB50细胞培养上清液中的VEGF蛋白浓度(187.69±83.89)μg/L显著低于阴性对照(822.98±187.98)μg/L和空白对照(865.76±170.33)μg/L(P<0.01)。p4.1CMV-VEGF shRNA处理的HXO-RB44细胞培养上清液中的VEGF蛋白浓度(162.20±66.33)μg/L与阴性对照(764.33±164.79)μg/L及空白对照(828.22±145.94)μg/L之间也存在显著差异(P<0.01)。
VEGF shRNA表达质粒的稳定转染可有效抑制RB细胞中的VEGF表达。靶向VEGF的RNA干扰(RNAi)有望成为研究RB治疗的重要工具。